NMD4C Investigators Submit Response to CDA Draft Guidance on NBS

On behalf of its Newborn Screening (NBS) Advisory Panel, Canada’s Drug Agency (CDA) recently published a discussion paper outlining its approach for developing Canadian newborn screening guidance. The goal of this discussion paper is to outline the foundations for a set of national guidelines for provincial and territorial governments to inform the development of their NBS programs. CDA have issued a call for input in response to this paper, providing an opportunity for the Canadian healthcare community to help shape the formation of these national NBS guidelines.

A group of NMD4C investigators submitted a response to this discussion paper, led by network co-lead Dr. Homira Osman, with input from neuromuscular experts including Dr. James Dowling, Dr. Hanns Lochmüller, Dr. Alex MacKenzie, Dr. Hugh McMillan, Dr. Maryam Oskoui, Dr. Kathryn Selby and Dr. Pranesh Chakraborty.

The author group noted that while the discussion paper from the CDA outlines important aspects of newborn screening, it fails to address critical issues related to infrastructure, national standards, and the integration of emerging technologies. The group identified that a broader approach is needed—one that encourages innovation, addresses systemic lab issues, and ensures equitable implementation across all provinces.

The authors recommended the creation of a national framework that sets minimum standards while allowing for the necessary flexibility to adopt new treatments and technologies as they become available. The system must be prepared for the future, and free from rigid processes that prevent timely advancements.

For any questions about future group recommendations from the network, please contact Dr. Homira Osman at .

newborn screening

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.